A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine (Q30228084)

11 June 2017

1 reference

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine (English)

1 reference

11 June 2017

phase I clinical trial

0 references

1 reference

Wendy Barclay

10

0 references

Maria Zambon

12

object named as

Maria Zambon

1 reference

11 June 2017

1

Rebecca J Cox

1 reference

11 June 2017

Abdullah S Madhun

2

1 reference

11 June 2017

Solveig Hauge

3

1 reference

11 June 2017

Haakon Sjursen

4

1 reference

11 June 2017

Diane Major

5

1 reference

11 June 2017

Mirjam Kuhne

6

1 reference

11 June 2017

Katja Höschler

7

1 reference

11 June 2017

Melanie Saville

8

1 reference

11 June 2017

Frederick R Vogel

9

1 reference

11 June 2017

Isabella Donatelli

11

1 reference

11 June 2017

John Wood

13

1 reference

11 June 2017

Lars R Haaheim

14

1 reference

11 June 2017

language of work or name

English

0 references

publication date

2 February 2009

1 reference

11 June 2017

1 reference

11 June 2017

27

1 reference

11 June 2017

13

1 reference

11 June 2017

1889-1897

1 reference

Human illness from avian influenza H7N3, British Columbia

11 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Avian influenza virus isolated from a woman with conjunctivitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Characterisation of an avian influenza A virus isolated from a human--is an intermediate host necessary for the emergence of pandemic influenza viruses?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Reference viruses for seasonal and pandemic influenza vaccine preparation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Eight-plasmid system for rapid generation of influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Confronting the avian influenza threat: vaccine development for a potential pandemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Vaccines for an influenza pandemic: scientific and political challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

The 1999-2000 avian influenza (H7N1) epidemic in Italy: veterinary and human health implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Local and systemic cytokine and chemokine responses after parenteral influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Parenteral influenza vaccination induces a rapid systemic and local immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Containing pandemic influenza at the source.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Strategies for mitigating an influenza pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

inferred from DOI database lookup

7 January 2021

based on heuristic

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.116

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.01.116

1 reference

11 June 2017

1 reference